Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

Maastricht, The Netherlands, 28 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from

Cristal Therapeutics progresses nanomedicine CriPec®-docetaxel to phase 1b development in patients with solid tumours

Maastricht, The Netherlands, 1 November 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announced today that it has begun a Phase 1b clinical program

Dr. Istvan Udvaros joins Cristal Therapeutics as New Chief Medical Officer

Maastricht, The Netherlands, 24 October 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Istvan Udvaros as its Chief Medical Officer

Cristal Therapeutics further strengthens its Scientific Advisory Board with appointment of Dr. Paul Lammers

Cristal Therapeutics Further Strengthens its Scientific Advisory Board with Appointment of Dr Paul Lammers Maastricht, The Netherlands, August 9, 2017 – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures Funding used: to execute clinical phase Ib and phase IIa

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform

Initial goal to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates   Maastricht, The Netherlands and Gosselies, Belgium – December 7th, 2016

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

Maastricht, The Netherlands, April 28, 2016 – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. He

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

Maastricht, The Netherlands, September 29, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel in

Cristal Therapeutics Announces Collaboration With PX Biosolutions to Develop CriVac® Based vaccines

Maastricht, The Netherlands, July 14, 2015 – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia).

Cristal Therapeutics’ proprietary CriPec® nanomedicine platform and promising preclinical data highlighted in three recent publications

Maastricht, The Netherlands, 22 June, 2015 – Cristal Therapeutics, a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases by using its proprietary CriPec® platform, today announced the publication of three articles on CriPec®-based nanomedicines in Nano Today,